RecruitingPhase 2NCT06268093

The Therapeutic Effect of Thalidomide in Syringomyelia

Studying Syringomyelia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Xuanwu Hospital, Beijing
Principal Investigator
fengzeng jian
Xuanwu Hospital, Beijing
Intervention
Thalidomide(drug)
Enrollment
30 target
Eligibility
18-80 years · All sexes
Timeline
2024 – 2028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06268093 on ClinicalTrials.gov

Other trials for Syringomyelia

Additional recruiting or active studies for the same condition.

See all trials for Syringomyelia →

← Back to all trials